Small Molecule Kinase Inhibitors Market to Reach Millions of US$ by 2015

The global small molecule kinase inhibitors market is projected to reach significant revenue, driven by the increasing demand for targeted cancer therapies and the approval of several new drugs in the pipeline. The market is diversified into various product segments, with Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, Tykerb/Tyverb, and Others being the key players.

Key Takeaways:

• The small molecule kinase inhibitors market is projected to reach $2.5 billion by 2015, growing at a CAGR of 14.3% from 2006 to 2015.
• The market is dominated by companies such as Amgen, Inc., AstraZeneca plc., Bristol-Myers Squibb Company, and GlaxoSmithKline plc.
• Gleevec/Glivec is the largest product segment, accounting for 24.1% of the market share in 2009, followed by Tarceva and Sutent.
• The market is expected to be driven by the increasing prevalence of cancer, as well as the introduction of new drugs and the expansion of existing products in the pipeline.
• The report profiles 83 companies, including many key and niche players worldwide.
• The market data and analytics are derived from primary and secondary research, with company profiles extracted from URL research and select online sources.

Statistics:

• The small molecule kinase inhibitors market is projected to reach $2.5 billion by 2015 (Source: Companies and Markets).
• The market is expected to grow at a CAGR of 14.3% from 2006 to 2015 (Source: Companies and Markets).
• The largest product segment in 2009 was Gleevec/Glivec, with a market share of 24.1% (Source: Companies and Markets).

Sources:

• Companies and Markets: Report: Clinical Phase Transition Percentage for Novel Kinase Inhibitor Compounds in Clinical Development - All Drugs Vs Kinase Inhibitors, During the Period (1995-2007).
• Companies and Markets: Small Molecule Kinase Inhibitors: New Company and Market Analysis.